These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15243577)

  • 1. The vital osteoclast: how is it regulated?
    Aeschlimann D; Evans BA
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S5-7. PubMed ID: 15243577
    [No Abstract]   [Full Text] [Related]  

  • 2. Signal transduction pathways regulating osteoclast differentiation and function.
    Tanaka S; Nakamura I; Inoue J; Oda H; Nakamura K
    J Bone Miner Metab; 2003; 21(3):123-33. PubMed ID: 12720046
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Regulatory mechanisms of osteoclast differentiation and function].
    Takahashi N
    Clin Calcium; 2006 Jun; 16(6):940-47. PubMed ID: 16751689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Commitment and differentiation of osteoclast on stromal cells].
    Yamazaki H; Hayashi S
    Tanpakushitsu Kakusan Koso; 1999 Jun; 44(7):854-64. PubMed ID: 10380577
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteoclast signalling pathways.
    Blair HC; Robinson LJ; Zaidi M
    Biochem Biophys Res Commun; 2005 Mar; 328(3):728-38. PubMed ID: 15694407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) stimulates osteoclast differentiation in response to receptor activator of NF-kappaB ligand (RANKL) in osteoclast cells.
    Shin HH; Kim SJ; Lee DS; Choi HS
    Bone; 2005 May; 36(5):832-9. PubMed ID: 15814301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANKL-mediated osteoclast formation from murine RAW 264.7 cells.
    Collin-Osdoby P; Yu X; Zheng H; Osdoby P
    Methods Mol Med; 2003; 80():153-66. PubMed ID: 12728717
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M; Amano S
    J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors.
    Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ
    Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation.
    Iwamoto K; Miyamoto T; Sawatani Y; Hosogane N; Hamaguchi I; Takami M; Nomiyama K; Takagi K; Suda T
    Biochem Biophys Res Commun; 2004 Dec; 325(1):229-34. PubMed ID: 15522223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synovial fluid macrophages are capable of osteoclast formation and resorption.
    Adamopoulos IE; Sabokbar A; Wordsworth BP; Carr A; Ferguson DJ; Athanasou NA
    J Pathol; 2006 Jan; 208(1):35-43. PubMed ID: 16278818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L; Schwarz EM; Boyce BF
    Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
    Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
    Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
    Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function.
    Liu W; Xu D; Yang H; Xu H; Shi Z; Cao X; Takeshita S; Liu J; Teale M; Feng X
    J Biol Chem; 2004 Dec; 279(52):54759-69. PubMed ID: 15485878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
    Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
    Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.